International GBS Outcome Study (IGOS)
Date published: April 18, 2024
International GBS Outcome Study (IGOS)
Worldwide research into the cause, diagnosis, treatment and prognosis of GBS.
Background:
Guillain-Barré Syndrome (GBS) is an inflammation of the nerves that can lead to rapidly progressive and very severe paralysis of the arms, legs and respiratory muscles. GBS is usually caused by the immune response to an infection. GBS can be treated with immunoglobulins, but some patients can still die or be left with serious disabilities from GBS. Other patients recover completely and without complaints. It is unknown how the course of the disease can vary so much from patient to patient. The type of infection and immune response may play an important role, in addition to other factors such as age, the type of GBS and local treatment. To understand and predict the disease mechanism and clinical course, it is necessary to systematically collect data and biomaterials (blood and cerebrospinal fluid) from many patients from the onset of the disease. In the IGOS, neurologists and scientists from more than 150 hospitals from 20 countries work together to answer these questions about GBS.
Aim:
The purpose of the IGOS is to find out which factors determine whether someone will get GBS and the severity with which the the disease will progress. We hope that with this global study we can better predict the course of the disease in individual patients in the future and treat patients better.
Current situation:
The target number of 2000 inclusions was reached in May 2021. The follow-up of the patients will finish in May 2024.
A list of research articles
-
The role of B lymphocytes in the progression of chronic immune-mediated neuropathies
-
Study on CIDP
In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.
-
-
Detecting anti-paranodal antibodies
-
Study on GBS
My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).
-
-
Time to treatment study
-
Study on GBS
In this project, we aim to describe the current practice of time to treatment. We also assess the association with functional outcome in patients with GBS who received first-line treatment with intravenous immunoglobulin or plasma exchange. This study is performed using data from the International GBS Outcome Study (IGOS).
-
